Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | CA1 | P00915 | 3/20 | 0.36 |
| ▸ | CA2 | P00918 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMYD3 | Q9H7B4 | 1/20 | 0.34 |
| ▸ | PRCP | P42785 | 1/20 | 0.33 |
| ▸ | PNMT | P11086 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3139036 | 0.75 | GAA (0.47) | GAAMAPTCA1CA2SMYD3 | |
| SCHEMBL2658519 | 0.74 | GAA (0.46) | GAAMAPTMEN1KMT2ASMYD3 | |
| SCHEMBL517885 | 0.72 | SMYD3 (0.43) | GAAMAPTCA1CA2SMYD3 | |
| SCHEMBL31634875 | 0.72 | SMYD3 (0.43) | GAAMAPTCA1CA2SMYD3 | |
| SCHEMBL3468367 | 0.72 | MEN1 (0.40) | GAAMAPTMEN1KMT2APRCP | |
| SCHEMBL31145667 | 0.72 | MEN1 (0.40) | GAAMAPTMEN1KMT2APRCP | |
| SCHEMBL26606581 | 0.71 | — | — | |
| Carbamic Acid SCHEMBL1271067 | 0.70 | SMYD3 (0.44) | GAAMAPTCA1CA2KMT2A | |
| SCHEMBL19676469 | 0.70 | PNMT (0.41) | GAAMAPTMEN1KMT2APRCP | |
| SCHEMBL27678136 | 0.69 | PNMT (0.50) | CA1CA2PRCPPNMT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2023154913-A1 | INHIBITORS OF PARG | ARASE THERAPEUTICS INC. (US) | 2023-08-17 | — | — | WO | claimed |
| CN-105272904-B | N- phenylamide compound and its application | 中国科学院广州生物医药与健康研究院 | 2019-04-09 | — | — | CN | claimed |
| WO-2024023330-A1 | SUBSTITUTED BICYCLIC HETEROARYL SULFONAMIDE DERIVATIVES FOR THE TREATMENT OF CANCER | NODUS ONCOLOGY LIMITED (GB) | 2024-02-01 | — | — | WO | disclosed |
| WO-2023175185-A1 | 2,4-DIOXO-1,4-DIHYDROQUINAZOLINE DERIVATIVES AS PARG INHIBITORS FOR THE TREATMENT OF CANCER | FORX THERAPEUTICS AG (CH) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023175184-A1 | 2,4-DIOXO-1,4-DIHYDROQUINAZOLINE DERIVATIVES AS PARG INHIBITORS FOR THE TREATMENT OF CANCER | FORX THERAPEUTICS AG (CH) | 2023-09-21 | — | — | WO | disclosed |
| WO-2023154913-A1 | INHIBITORS OF PARG | ARASE THERAPEUTICS INC. (US) | 2023-08-17 | — | — | WO | disclosed |
| EP-3716968-A1 | SIGMA-1 RECEPTOR AGONIST SYSTOLIC BLOOD PRESSURE THERAPY | Anavex Life Sciences Corp. (US) | 2020-10-07 | — | — | EP | disclosed |